![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
CYGS is a biotech working on anti aging and cancer cures. The float is less than 3 million . 10 million shares have been authorized . Sixty percent (60%) of shares outstanding are held by the principals. There is a short interest of 160,000 shares. CYGS is in play due to GERN news today. CYGS and GERN are both in the area of study of telemerase or telemeres. CYGS could be a big mover on its on merit and in sympathy with GERN which moved 10 points today. | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |